31 research outputs found
Recommended from our members
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We found that ATP-competitive RAF inhibitors inhibit ERK signalling in cells with mutant BRAF, but unexpectedly enhance signalling in cells with wild-type BRAF. Here we demonstrate the mechanistic basis for these findings. We used chemical genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors. Induction of ERK signalling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity. Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer. In BRAF(V600E) tumours, RAS is not activated, thus transactivation is minimal and ERK signalling is inhibited in cells exposed to RAF inhibitors. These results indicate that RAF inhibitors will be effective in tumours in which BRAF is mutated. Furthermore, because RAF inhibitors do not inhibit ERK signalling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumour activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation. These predictions have been borne out in a recent clinical trial of the RAF inhibitor PLX4032 (refs 4, 5). The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumours. In agreement with this prediction, RAF inhibitors do not inhibit ERK signalling in cells that coexpress BRAF(V600E) and mutant RAS
Inhibitors of BRAF dimers using an allosteric site
FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which limits their clinical efficacy in tumors expressing BRAFV600E mutant monomers. Here the authors identify FDA-approved Ponatinib as an effective inhibitor of BRAF monomers and dimers and designed PHI1, an inhibitor with a unique mode of action and selectivity for oncogenic BRAF dimers
RELIEF OF PROFOUND FEEDBACK INHIBITION OF MITOGENIC SIGNALING BY RAF INHIBITORS ATTENUATES THEIR ACTIVITY IN BRAFV600E MELANOMAS
BRAFV600E drives tumors by dysregulating ERK signaling. Here we show that, in these
tumors, high levels of ERK-dependent negative feedback potently suppress liganddependent
mitogenic signaling and Ras function. BRAFV600E activation is Rasindependent
and signals as a RAF-inhibitor sensitive monomer. RAF inhibitors potently
inhibit RAF monomers and ERK signaling, causing relief of ERK-dependent feedback,
reactivation of ligand-dependent signal transduction, increased Ras-GTP and generation
of RAF inhibitor-resistant RAF dimers. This results in a rebound in ERK activity and
culminates in a new steady state, wherein ERK signaling is elevated compared to its
initial nadir after RAF inhibition. In this state, ERK signaling is RAF inhibitor resistant,
and MEK inhibitor sensitive, and combined inhibition results in enhancement of ERKpathway
inhibition and antitumor activity